Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.

The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina and 454 for the detection of HIV-1 raltegravir-res...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS ONE
Autori principali: Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, ACTG A5262 Study Team, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings
Natura: Articolo
Pubblicazione: Public Library of Science (PLoS) 2014-01-01
Accesso online:http://europepmc.org/articles/PMC3946168?pdf=render
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Accesso online

http://europepmc.org/articles/PMC3946168?pdf=render

Documenti analoghi